PharmEng signs letter of intent to buy controlling stake in Lixin PharmaTech

By Ted A. Knutson

Washington, March 9 - PharmEng International Inc. said Thursday it has signed a letter of intent to purchase a controlling interest in Beijing BRD Lixin PharmaTech Co. Ltd. The price of the deal was not disclosed.

Lixin specializes in providing consulting services in the areas of good manufacturing practices (GMP), validation and engineering design to more than 100 pharmaceutical manufacturers.

Lixin's clients, located throughout China, manufacture powders for injection, solutions for injections, oral liquids and other extracts used in Chinese medicines and other drug products. GMP consultation services are also provided to veterinary medicine manufacturers.

Lixin, with its client base, will provide PharmEng with a resource of manufacturers for the supply of active pharmaceutical ingredients for PharmEng's contract manufacturing division in addition to giving PharmEng a solid base for the expansion of consulting opportunities in China.

PharmEng is a Toronto-based full-service consulting and contract manufacturing company that serves the pharmaceutical and biotechnology industries in North America and internationally.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.